GlassScriptPhysician profile
Sarah A Altamimi
NPI 1467746529
$2,152.69
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $787 · 2020: $71.14 · 2021: $467 · 2022: $828.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $516.49 | 2019-2022 | |
| Abbvie INC. | $354.07 | 2019-2022 | |
| Gilead Sciences, INC. | $278.31 | 2019-2022 | |
| Allergan, INC. | $272.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $219.96 | 2019-2022 | |
| Shionogi INC | $133.65 | 2022 | |
| Paratek Pharmaceuticals, INC. | $116.60 | 2022 | |
| Boston Scientific Corporation | $82.16 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $58.59 | 2019-2022 | |
| Insmed, INC. | $53.15 | 2021-2022 | |
| Janssen Biotech, INC. | $35.63 | 2019 | |
| Melinta Therapeutics, LLC | $31.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Altamimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.